Investors meetings
Category: Press release
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Eligibility PEA-PME
Transgene To Participate in the Biomed Forum Investor Conference
BIOMED FORUM
Transgene Announces Financial Calendar for 2025
calendrier 2025
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
SITC 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Financial Q3 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
ProBioGen
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
TG4001 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
H1 2024 FINANCIAL RESULTS